Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 6Thoracic 2Gastrointestinal 2Dermatologic 2Other hematologic neoplasm 1Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Pancreatic Neoplasms 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

pembrolizumab 183Cisplatin 159Radiotherapy 78Carboplatin 71Radiotherapy, Intensity-Modulated 70Cetuximab 68Magnetic Resonance Spectroscopy 65Nivolumab 64Paclitaxel 52Docetaxel 50Specimen Handling 45Radiation 35Gemcitabine 33Fluorouracil 31Surveys and Questionnaires 28Biopsy 27toripalimab 26Drug Therapy 26Platinum 25Surgical Procedures, Operative 24Standard of Care 231,2-diaminocyclohexaneplatinum II citrate 23cemiplimab 22atezolizumab 21Capecitabine 20Ipilimumab 19Chemoradiotherapy 19tislelizumab 18durvalumab 18Taxes 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
tovorafenib × Head & Neck × 1 year × Clear all
NCT04985604 2025-10-02

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Day One Biopharmaceuticals, Inc.

Phase 2 Terminated
23 enrolled 15 charts
CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckThoracic

Thyroid Cancer, Papillary, Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡